share_log

康哲药业2024年营收74.69亿元 同比下降6.8%

CMS's revenue for 2024 is 7.469 billion yuan, a year-on-year decrease of 6.8%.

Breakings ·  Mar 17 14:52

On the evening of March 17, CMS released its performance for 2024, achieving a total revenue of 7.469 billion yuan, which is a year-on-year decrease of 6.8%. The company realized a net income of 1.613 billion yuan for the year, and the normalized net income after excluding related asset impairment losses is 1.714 billion yuan. It is reported that the performance decline is mainly influenced by the implementation of national procurement. The revenue from three unselected original research drugs decreased by 28.8% year-on-year to 2.691 billion yuan in 2024. This impact is expected to be absorbed by 2025. For other core products except for these three, the majority are exclusive and innovative products. The revenue from exclusive and innovative products in 2024 is 4.551 billion yuan, an increase of 4.1% year-on-year, making up 52.8% of the total revenue.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 336

Recommended

Write a comment

Statement

This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.